An alphavirus vector-based tetravalent dengue vaccine induces a rapid and protective immune response in macaques that differs qualitatively from immunity induced by live virus infection.
about
Alphavirus-based vaccinesVaccines in development against West Nile virusMouse models to study dengue virus immunology and pathogenesisReplicon RNA Viral Vectors as VaccinesCharacterization of the ectodomain of the envelope protein of dengue virus type 4: expression, membrane association, secretion and particle formation in the absence of precursor membrane protein.An alphavirus-based adjuvant enhances serum and mucosal antibodies, T cells, and protective immunity to influenza virus in neonatal miceUtility, limitations, and future of non-human primates for dengue research and vaccine developmentDengue vaccines: recent developments, ongoing challenges and current candidates.Kinetic and phenotypic analysis of CD8+ T cell responses after priming with alphavirus replicons and homologous or heterologous booster immunizationsRole of humoral versus cellular responses induced by a protective dengue vaccine candidate.The protein DIIIC-2, aggregated with a specific oligodeoxynucleotide and adjuvanted in alum, protects mice and monkeys against DENV-2.Immunogenicity and efficacy of flagellin-envelope fusion dengue vaccines in mice and monkeys.A tetravalent alphavirus-vector based dengue vaccine provides effective immunity in an early life mouse modelA new quaternary structure epitope on dengue virus serotype 2 is the target of durable type-specific neutralizing antibodies.High-avidity and potently neutralizing cross-reactive human monoclonal antibodies derived from secondary dengue virus infection.Induction of neutralizing antibodies against four serotypes of dengue viruses by MixBiEDIII, a tetravalent dengue vaccineDengue virus envelope protein domain I/II hinge determines long-lived serotype-specific dengue immunity.Self-replicating alphavirus RNA vaccines.The alien replicon: Artificial genetic constructs to direct the synthesis of transmissible self-replicating RNAs: In vivo synthesised heterologous (alien) RNA constructs are capable of initiating self-replication following transmission to the host oChanges in cellular mRNA stability, splicing, and polyadenylation through HuR protein sequestration by a cytoplasmic RNA virusKey concepts, strategies, and challenges in dengue vaccine development: an opportunity for sub-unit candidates?The tetravalent formulation of domain III-capsid proteins recalls memory B- and T-cell responses induced in monkeys by an experimental dengue virus infection.Use of a Recombinant Gamma-2 Herpesvirus Vaccine Vector against Dengue Virus in Rhesus Monkeys.Could an experimental dengue virus infection fail to induce solid immunity against homologous viral challenge in non-human primates?Innovation, urgency and acceptance at the 9th Vaccine Renaissance.Development of a Broadly Accessible Venezuelan Equine Encephalitis Virus Replicon Particle Vaccine Platform.Dengue vaccine development: challenges and emerging opportunitiesRecent Developments in Recombinant Protein-Based Dengue Vaccines
P2860
Q26994724-65FE25A7-A6FE-4F8A-9E65-A26C22EDC23FQ26999702-B226926F-6A95-4B23-9190-075FACE9A580Q27010151-6FE65967-3719-46F0-90F7-CFCF0AB4658DQ28076639-9A3B7055-437B-4CC1-9A31-4B5248CF35AEQ33784307-98F341DE-65D0-4929-8EF0-1015673541B4Q34059308-6C1355DA-1A01-468D-BCFD-F0F7794256B3Q34238916-0B1F49D5-A6D8-4DBE-9CA6-EAC53E7BA869Q34367194-4D7F4A1E-327A-43DD-9BB3-DBC5A5C20E17Q34593874-B710E3D4-D042-41EC-89AA-75F5C1FE9572Q35034240-546B7DB9-0975-446B-A909-7045091BD7A8Q35236379-2D496DBC-D74F-4BEC-B0D4-4A7A25918ED2Q35548048-F8B5815D-F6EC-4A0A-BD39-9A0018248906Q35806060-6513B219-A338-433C-804A-079095D6938FQ36205859-6BF7C921-2317-4C16-B905-3DC4EF4FF929Q37336440-46269CBF-7DB7-4BE6-98A5-4286FAAA30C0Q37500519-589B7221-9CE0-44E0-B79D-9381558D915FQ37571377-F3CE7174-70F1-49ED-9AD0-930118F60679Q38255634-54C7ED67-7D85-49D0-AF1A-93FA9AF58414Q38266429-B8755CE8-41BB-4178-9F87-FF291201D433Q38444904-1F7983E2-272B-4110-8079-53142D197B58Q38618056-9956ADF2-E0A6-442C-B382-576BD886D1B5Q39023330-822C1266-E359-4C27-A4FF-823CF9DB85DFQ40053434-07DF0104-C1B4-4619-B51F-5B009DF94669Q40130106-48E44B99-074D-4FFE-93EC-B1BBDE72758EQ50285179-C8BD7A3D-5002-405E-9EC2-902579A2764CQ51783750-FD829EE0-BE80-4D92-B233-B3E2C324C7B8Q53158319-CA6AD449-85AA-497B-883C-5E6FBE94A3E7Q56960671-7E148316-F7CB-4E15-9324-C40220328035
P2860
An alphavirus vector-based tetravalent dengue vaccine induces a rapid and protective immune response in macaques that differs qualitatively from immunity induced by live virus infection.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
An alphavirus vector-based tet ...... duced by live virus infection.
@ast
An alphavirus vector-based tet ...... duced by live virus infection.
@en
type
label
An alphavirus vector-based tet ...... duced by live virus infection.
@ast
An alphavirus vector-based tet ...... duced by live virus infection.
@en
prefLabel
An alphavirus vector-based tet ...... duced by live virus infection.
@ast
An alphavirus vector-based tet ...... duced by live virus infection.
@en
P2093
P2860
P356
P1433
P1476
An alphavirus vector-based tet ...... duced by live virus infection.
@en
P2093
Carlos A Sariol
Idia V Rodriguez
Jill Whitley
Laura J White
Martha L Collier
Melissa D Mattocks
Melween I Martinez
Robert E Johnston
Rochelle Mikkelsen
Vorraphun Yingsiwaphat
P2860
P304
P356
10.1128/JVI.02298-12
P407
P577
2013-01-09T00:00:00Z